A clinical case of sorafenib use in the treatment of hepatocellular carcinoma

Abstract

Treatment of patients with hepatocellular carcinoma is a topical issue of modern oncology. This disease is included by the World Health Organization in the list of 130 major causes of morbidity and mortality. The paper describes a clinical case of hepatocellular carcinoma in a patient treated with three action methods: the antitumor drug sorafenib at a dose of 400 mg orally twice daily, hepatic transarterial chemoembolization (performed 5 times) and surgical treatment as extended left hemihepatectomy, cholecystectomy with resection of the bile duct confluence and reconstruction of the right hepatic and S 1 ducts on the frame drainage by Pikovsky, lymphadenectomy of the hepatoduodenal ligament. It demonstrates the efficiency of combining the above three methods (the female patient receives the treatment for 24 months; her condition is satisfactory, ECOG grade 0).